Valproic acid induces differentiation of a supratentorial primitive neuroectodermal tumor

被引:19
作者
Driever, PH
Wagner, S
Hofstädter, F
Wolff, JEA
机构
[1] Charite Univ Med Berlin, Dept Pediat Oncol, Campus Virchow Hosp, Berlin, Germany
[2] Regensburg Univ, Inst Pathol, Med Ctr, Regensburg, Germany
[3] St Hedwig Childrens Hosp, Dept Pediat Oncol, Regensburg, Germany
关键词
differentiation induction; glial maturation; supratentorial primitive neuroectodermal tumor; valproic acid;
D O I
10.1080/08880010490514985
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In preclinical models the antiepileptic drug valproic acid induces differentiation of neoplastic cells, representing an evolving anticancer approach that takes into account that malignant cells resemble immature progenitor cells capable of terminal differentiation. The authors report on a child suffering from a relapsing supratentorial primitive neuroectodermal tumor that received valproic acid for epilepsy treatment over 7 months before the relapse. In contrast to the initial tumor, the relapsing tumor showed glial differentiation and low proliferation index. This is the first report of a relapsed supratentorial primitive neuroectodermal tumor that shows histologically confirmed signs of tumor cell differentiation induction.
引用
收藏
页码:743 / 751
页数:9
相关论文
共 28 条
[1]   Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate [J].
Baker, MJ ;
Brem, S ;
Daniels, S ;
Sherman, B ;
Phuphanich, S .
JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (03) :239-242
[2]   Anti-tumor mechanisms of valproate: A novel role for an old drug [J].
Blaheta, RA ;
Cinatl, J .
MEDICINAL RESEARCH REVIEWS, 2002, 22 (05) :492-511
[3]   Valproate and valproate-analogues: Potent tools to fight against cancer [J].
Blaheta, RA ;
Nau, H ;
Michaelis, M ;
Cinatl, J .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (15) :1417-1433
[4]   Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma [J].
Buckner, JC ;
Malkin, MG ;
Reed, E ;
Cascino, TL ;
Reid, JM ;
Ames, MM ;
Tong, WPY ;
Lim, S ;
Figg, WD .
MAYO CLINIC PROCEEDINGS, 1999, 74 (02) :137-145
[5]   Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium report [J].
Chang, SM ;
Kuhn, JG ;
Robins, HI ;
Schold, SC ;
Spence, AM ;
Berger, MS ;
Mehta, MP ;
Bozik, ME ;
Pollack, I ;
Schiff, D ;
Gilbert, M ;
Rankin, C ;
Prados, MD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :984-990
[6]   On the epigenetic regulation of the human reelin promoter [J].
Chen, Y ;
Sharma, RP ;
Costa, RH ;
Costa, E ;
Grayson, DR .
NUCLEIC ACIDS RESEARCH, 2002, 30 (13) :2930-2939
[7]   Antitumor activity of sodium valproate in cultures of human neuroblastoma cells [J].
Cinatl, J ;
Cinatl, J ;
Scholz, M ;
Driever, PH ;
Henrich, D ;
Kabickova, H ;
Vogel, JU ;
Doerr, HW ;
Kornhuber, B .
ANTI-CANCER DRUGS, 1996, 7 (07) :766-773
[8]   Sodium valproate inhibits in vivo growth of human neuroblastoma cells [J].
Cinatl, J ;
Cinatl, J ;
Driever, PH ;
Kotchetkov, R ;
Pouckova, P ;
Kornhuber, B ;
Schwabe, D .
ANTI-CANCER DRUGS, 1997, 8 (10) :958-963
[9]   All-trans retinoic acid in relapsing malignant gliomas: Clinical and radiological stabilization associated with the appearance of intratumoral calcifications [J].
Defer, GL ;
AdleBiassette, H ;
Ricolfi, F ;
Martin, L ;
Authier, FJ ;
Chomienne, C ;
Degos, L ;
Degos, JD .
JOURNAL OF NEURO-ONCOLOGY, 1997, 34 (02) :169-177
[10]   Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo [J].
Deininger, MH ;
Grote, E ;
Wickboldt, J ;
Meyermann, R .
JOURNAL OF NEURO-ONCOLOGY, 2000, 48 (02) :121-129